NT-501 ECT is currently in development for retinal degenerative diseases. NT-501 ECT delivers ciliary neurotrophic factor (CNTF), a human growth factor that preferentially stimulates and protects neural cells, including photoreceptor cells responsible for detecting light in the retina.
Neurotech is conducting multiple clinical studies with NT-501 ECT, including trials in subjects with macular telangectasia (MacTel) and glaucoma.
More than 250 subjects have been enrolled in studies of Macular Telangiectasia, Retinitis Pigmentosa and Geographic Atrophy. Some subjects have completed more than 5 years of follow up.
Neurotech has discontinued the NT-503-3 Phase 2 program.